Country: Canada
Language: English
Source: Health Canada
TRAMADOL HYDROCHLORIDE
PURDUE PHARMA
N02AX02
TRAMADOL
75MG
TABLET (EXTENDED-RELEASE)
TRAMADOL HYDROCHLORIDE 75MG
ORAL
50/60
Narcotic (CDSA I)
OPIATE AGONISTS
Active ingredient group (AIG) number: 0151694007; AHFS:
APPROVED
2010-12-02
_ _ _ZYTRAM XL_ _®_ _ (tramadol HCl controlled release tablets) _ _Page 1 of 46_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION N ZYTRAM XL® Tramadol Hydrochloride Controlled Release Tablets, 75, 100, 150, 200, 300 and 400 mg, Oral Purdue Pharma Standard Opioid Analgesic ATC code: N02AX02 Purdue Pharma 3381 Steeles Avenue East, Suite 310 Toronto, Ontario M2H 3S7 Date of Initial Approval: Sept 28, 2006 Date of Revision: December 01, 2023 Submission Control Number: 274793 _ _ _ZYTRAM XL_ _®_ _ (tramadol HCl controlled release tablets) _ _Page 2 of 46_ RECENT MAJOR LABEL CHANGES 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 12/2023 7 WARNING AND PRECAUTIONS 12/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 5 4 DOSAGE AND ADMINISTRATION ................................................................................. 6 4.1 Dosing Considerations ............................................................................................ 6 4.2 Recommended Read the complete document